الفهرس 
Colorectal cancer
Inhibition of cancer cell proliferationOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
This study aimed at evaluating the safety and efficacy of celecoxib as adjuvant to chemotherapy in metastatic colorectal cancer patients. The study design was a prospective, randomized, controlled trial in which 54 eligible metastatic colorectal cancer patients were randomized into two groups; group 1 which received FOLFIRI regimen for 3months and group 2 which received FOLFIRI plus celecoxib 200 mg BID for 3 months. Blood samples were collected before and 3months after treatment for biochemical analysis of serum VEGF, FAS, FASL and CXCL5 levels. Also, assessment of tumor response via RECIST criteria was done . .
The results obtained with the current study showed that, the addition of celecoxib to FOLFIRI produced significant declines in serum levels of the biomarkers for angiogenesis (VEGF), apoptosis (sFAS and sFASL), and metastasis (CXCL5). Furthermore, the addition of celecoxib to FOLFIRI was associated with significant increase in sFAS/FASL ratio indicating chemo- sensitivity. Celecoxib showed anti-angiogenic and pro-apoptotic properties which resulted in enhancement of both objective response rate and disease control rate of metastatic colorectal cancer. Furthermore, celecoxib improved both progression-free survival and 1-year overall survival. Celecoxib was well tolerated and exhibited mild and controllable side effects.
We concluded that, celecoxib may represent an effective and safe adjuvant agent to chemotherapy for patients with metastatic colorectal cancer.